MY129282A - Aerosolizable particles resistant to hygroscopic growth - Google Patents

Aerosolizable particles resistant to hygroscopic growth

Info

Publication number
MY129282A
MY129282A MYPI99003947A MYPI9903947A MY129282A MY 129282 A MY129282 A MY 129282A MY PI99003947 A MYPI99003947 A MY PI99003947A MY PI9903947 A MYPI9903947 A MY PI9903947A MY 129282 A MY129282 A MY 129282A
Authority
MY
Malaysia
Prior art keywords
hygroscopic growth
particles resistant
active agent
aerosolizable particles
aerosolizable
Prior art date
Application number
MYPI99003947A
Inventor
Andrew Clark
Mei Chang Kuo
Cecily Lalor
Barry John Aldous
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MY129282A publication Critical patent/MY129282A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

THE PRESENT INVENTION IS DIRECTED TO PARTICULATE COMPOSITIONS AND METHODS FOR DELIVERING AN ACTIVE AGENT TO THE LUNG OF A HUMAN PATIENT. THE ACTIVE AGENT FORMULATION IS IN DRY POWDER FORM AND EXHIBITS (I) LOW MOISTURE SORPTION, AND (II) A RESISTANCE TO HYGROSCOPIC GROWTH, PARTICULARLY UNDER SIMULATED LUNG CONDITIONS.
MYPI99003947A 1998-09-14 1999-09-13 Aerosolizable particles resistant to hygroscopic growth MY129282A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
MY129282A true MY129282A (en) 2007-03-30

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99003947A MY129282A (en) 1998-09-14 1999-09-13 Aerosolizable particles resistant to hygroscopic growth

Country Status (44)

Country Link
EP (1) EP1117442A1 (en)
JP (1) JP2002524535A (en)
KR (1) KR20010075063A (en)
CN (1) CN1317977A (en)
AP (1) AP1374A (en)
AR (1) AR022090A1 (en)
AU (1) AU753014B2 (en)
BG (1) BG105430A (en)
BR (1) BR9913722A (en)
CA (1) CA2343920A1 (en)
CO (1) CO5130023A1 (en)
CZ (1) CZ2001829A3 (en)
DZ (1) DZ2892A1 (en)
EA (1) EA003476B1 (en)
EE (1) EE200100151A (en)
GE (1) GEP20043257B (en)
GT (1) GT199900156A (en)
HK (1) HK1042231A1 (en)
HN (1) HN1999000159A (en)
HR (1) HRP20010189A2 (en)
HU (1) HUP0103837A3 (en)
ID (1) ID28845A (en)
IL (2) IL141562A0 (en)
IS (1) IS5878A (en)
LT (1) LT4897B (en)
LV (1) LV12658B (en)
MA (1) MA25590A1 (en)
MY (1) MY129282A (en)
NO (1) NO20011251L (en)
NZ (1) NZ510168A (en)
OA (1) OA11781A (en)
PA (1) PA8481901A1 (en)
PE (1) PE20001061A1 (en)
PL (1) PL195574B1 (en)
SA (1) SA99200718B1 (en)
SK (1) SK3442001A3 (en)
TN (1) TNSN99173A1 (en)
TR (1) TR200101182T2 (en)
TW (1) TWI226248B (en)
UA (1) UA76085C2 (en)
UY (1) UY25711A1 (en)
WO (1) WO2000015262A1 (en)
YU (1) YU24201A (en)
ZA (1) ZA200101995B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
CZ2004904A3 (en) 2002-02-25 2004-12-15 Diffusion Pharmaceuticals Llc Bipolar carotenoid salts and use thereof
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
MXPA05006802A (en) * 2002-12-19 2005-09-08 Pharmacia Corp Non-hygroscopic formulation comprising a hydroscopic drug.
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2005104712A2 (en) * 2004-04-23 2005-11-10 Cydex, Inc. Dpi formulation containing sulfoalkyl ether cyclodextrin
CN104840455A (en) 2005-02-24 2015-08-19 扩散药品有限公司 Trans carotenoids, their synthesis, formulation and uses
AU2006221364A1 (en) * 2005-03-09 2006-09-14 Ono Pharmaceutical Co., Ltd. Particle and preparation containing the particle
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PL2581078T3 (en) 2005-10-26 2015-07-31 Cydex Pharmaceuticals Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
WO2008050847A1 (en) * 2006-10-25 2008-05-02 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
EP2146948A4 (en) 2007-04-13 2010-08-04 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
MX2010004803A (en) 2007-10-31 2010-09-09 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion.
PL2432502T3 (en) 2009-05-20 2018-05-30 Aeras Stable, spray dried, immunogenic, viral compositions
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
CN103124498A (en) 2010-06-02 2013-05-29 扩散药品有限公司 Oral formulations of bipolar trans carotenoids
KR102240042B1 (en) 2012-05-03 2021-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
WO2015042352A1 (en) * 2013-09-20 2015-03-26 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
MX2017005692A (en) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Powder formulation.
KR102489034B1 (en) 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 Use of Bipolar Trans Carotenoids with Chemotherapy and Radiation Therapy to Treat Cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
DE69332240T2 (en) * 1992-06-12 2003-04-10 Teijin Ltd ULTRA FINE POWDER FOR INHALATION AND PRODUCTION
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ES2236832T3 (en) * 1997-01-16 2005-07-16 Massachusetts Institute Of Technology PREPARATION OF PARTICLES FOR INHALATION.
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
AR022090A1 (en) 2002-09-04
LT2001021A (en) 2001-11-26
IL141562A (en) 2007-07-24
GT199900156A (en) 2001-03-07
DZ2892A1 (en) 2003-12-15
CN1317977A (en) 2001-10-17
UY25711A1 (en) 1999-11-17
CO5130023A1 (en) 2002-02-27
PA8481901A1 (en) 2002-04-25
LV12658A (en) 2001-05-20
PL195574B1 (en) 2007-10-31
AP2001002093A0 (en) 2001-03-31
BG105430A (en) 2001-12-29
HN1999000159A (en) 1999-11-11
EP1117442A1 (en) 2001-07-25
HK1042231A1 (en) 2002-08-09
NO20011251L (en) 2001-04-17
PL346768A1 (en) 2002-02-25
CA2343920A1 (en) 2000-03-23
EA003476B1 (en) 2003-06-26
LV12658B (en) 2001-09-20
HUP0103837A2 (en) 2002-05-29
TWI226248B (en) 2005-01-11
ZA200101995B (en) 2002-03-11
CZ2001829A3 (en) 2001-09-12
TNSN99173A1 (en) 2005-11-10
ID28845A (en) 2001-07-05
AU753014B2 (en) 2002-10-03
LT4897B (en) 2002-02-25
YU24201A (en) 2003-08-29
NO20011251D0 (en) 2001-03-13
HRP20010189A2 (en) 2005-04-30
SK3442001A3 (en) 2001-11-06
NZ510168A (en) 2003-09-26
OA11781A (en) 2005-07-26
EE200100151A (en) 2002-06-17
KR20010075063A (en) 2001-08-09
HUP0103837A3 (en) 2002-11-28
AU6039799A (en) 2000-04-03
GEP20043257B (en) 2004-06-25
SA99200718B1 (en) 2006-11-04
JP2002524535A (en) 2002-08-06
PE20001061A1 (en) 2000-10-08
BR9913722A (en) 2001-05-29
WO2000015262A1 (en) 2000-03-23
IS5878A (en) 2001-03-05
IL141562A0 (en) 2002-03-10
UA76085C2 (en) 2006-07-17
MA25590A1 (en) 2002-12-31
TR200101182T2 (en) 2001-09-21
AP1374A (en) 2005-02-28
EA200100300A1 (en) 2001-10-22

Similar Documents

Publication Publication Date Title
MY129282A (en) Aerosolizable particles resistant to hygroscopic growth
MY129112A (en) Flow resistance modulated aerosolized active agent delivery
DE59904488D1 (en) DRY POWDER FOR INHALATION
ES2178943A1 (en) Aerosol composition comprising formoterol
MX9702357A (en) Spray-dried microparticles as therapeutic vehicles.
GB1484781A (en) Compositions for dental treatment
HU9201521D0 (en) Stimulating unit containing nicotine
IS5108A (en) New inhalation formulation in bulk with a mass of 0.28 to 0.38 g / ml, method of preparation and use of the preparation
CA2412561A1 (en) Highly efficient delivery of a large therapeutic mass aerosol
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
AU6611998A (en) Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
IS5110A (en) New inhalation formulation in bulk with a mass of 0.28 to 0.38 g / ml containing budesonide
SE8300495D0 (en) IMPROVEMENTS IN OR RELATING TO NASAL PHARMACEUTICAL COMPOSITIONS
TH51990B (en) Release of the dry powdered active ingredient.
TH51990A3 (en) Release of the dry powdered active ingredient.